These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30341384)

  • 21. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
    Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
    Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.
    Chakrabarti M; Gabelli SB; Amzel LM
    Structure; 2020 Apr; 28(4):465-474.e5. PubMed ID: 32049032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
    Gkeka P; Papafotika A; Christoforidis S; Cournia Z
    J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
    Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
    Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
    Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mechanism of PI3Kα activation at the atomic level.
    Zhang M; Jang H; Nussinov R
    Chem Sci; 2019 Mar; 10(12):3671-3680. PubMed ID: 30996962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
    Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
    Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel all-hydrocarbon stapled p110α[E545K] peptides as blockers of the oncogenic p110α[E545K]-IRS1 interaction.
    Hu X; He Y; Wu L; Hao Y; Wang Z; Zheng W
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5446-5449. PubMed ID: 29138025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight.
    Sharma J; Bhardwaj V; Purohit R
    ACS Omega; 2019 Oct; 4(14):15815-15823. PubMed ID: 31592171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases.
    Zhang M; Jang H; Nussinov R
    J Mol Biol; 2020 Nov; 432(22):5849-5859. PubMed ID: 32918948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
    Ghodsinia AA; Lego JMT; Garcia RL
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
    Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
    Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Preexisting Rare
    Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
    Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
    Miller MS; Maheshwari S; McRobb FM; Kinzler KW; Amzel LM; Vogelstein B; Gabelli SB
    Bioorg Med Chem; 2017 Feb; 25(4):1481-1486. PubMed ID: 28129991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unravelling the effect of the E545K mutation on PI3Kα kinase.
    Galdadas I; Gervasio FL; Cournia Z
    Chem Sci; 2020 Apr; 11(13):3511-3515. PubMed ID: 34703536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
    Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z
    Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.